Erratum: E pluribus unum? The main protein kinase a catalytic subunit (PRKACA), a likely oncogene, and cortisol-producing tumors (Journal of Clinical Endocrinology and Metabolism (2014) 99:10 (3629-3633) DOI: 10.1210/jc.2014-3295);E pluribus unum? The main protein kinase a catalytic subunit (PRKACA), a likely oncogene, and cortisol-producing tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3629-3633

  Stratakis, Constantine A ^a,b,c  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NICHD   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR; HYDROCORTISONE; PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT; PRKACA PROTEIN, HUMAN;

ALBRIGHT SYNDROME; CARNEY COMPLEX; CORTISOL PRODUCING TUMOR; CUSHINGOID SYNDROME; DISEASE PREDISPOSITION; ENDOCRINE TUMOR; ENZYME ACTIVATION; GENE IDENTIFICATION; GENE LOCUS; GENE LOSS; GENE MUTATION; GENETIC CODE; GNAS1 GENE; HORMONE SYNTHESIS; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE; PATHOGENESIS; PDE11A GENE; PRIMARY MACRONODULAR HYPERPLASIA; PRIMARY PIGMENTED NODULAR ADRENOCORTICAL DISEASE; PRKACA GENE; PRKAR1A GENE; REVIEW; SIGNAL TRANSDUCTION; STEROIDOGENESIS; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX TUMOR; CUSHING SYNDROME; FEMALE; GENETICS; MALE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; CUSHING SYNDROME; CYCLIC AMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNITS; FEMALE; HUMANS; MALE;

EID: 84907637520     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4426     Document Type: Erratum

References (52)

1. Stratakis CA, Kirschner LS. Clinical and genetic analysis of primary bilateral adrenal diseases (micro- and macronodular disease) leading to Cushing syndrome. Horm Metab Res. 1998;30:456-463.
2. Stratakis CA. cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse. Mol Cell Endocrinol. 2013;371:208-220.
3. Carney JA, Young WF, Stratakis CA. Primary bimorphic adrenocortical disease: cause of hypercortisolism in McCune-Albright syndrome. Am J Surg Pathol. 2011;35:1311-1326.
4. Lacroix A. Heredity and cortisol regulation in bilateral macronodular adrenal hyperplasia. N Engl J Med. 2013;369:2147-2149.
5. De Venanzi A, Alencar GA, Bourdeau I, Fragoso MC, Lacroix A. Primary bilateral macronodular adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes. 2014;21:177-184.
6. Hsiao HP, Kirschner LS, Bourdeau I, et al. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab. 2009;94:2930-2937.
7. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-a regulatory subunit in patients with the Carney complex. Nat Genet. 2000;26:89-92.
8. Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum Mol Genet. 2000;9:3037-3046.
9. Bourdeau I, Matyakhina L, Stergiopoulos SG, Sandrini F, Boikos S, Stratakis CA. 17q22-24 chromosomal losses and alterations of protein kinase A subunit expression and activity in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab. 2006;91:3626-3632.
10. Bertherat J, Groussin L, Sandrini F, et al. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res. 2003;63:5308-5319.
11. Bimpaki EI, Nesterova M, Stratakis CA. Abnormalities of cAMP signaling are present in adrenocortical lesions associated with ACTH-independent Cushing syndrome despite the absence of mutations in known genes. Eur J Endocrinol. 2009;161:153-161.
12. Horvath A, Boikos S, Giatzakis C, et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet. 2006;38:794-800.
13. Boikos SA, Horvath A, Heyerdahl S, et al. Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions. Horm Metab Res. 2008;40:347-353.
14. Horvath A, Mericq V, Stratakis CA. Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia. N Engl J Med. 2008;358:750-752.
15. Horvath A, Giatzakis C, Tsang K, et al. A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. Eur J Hum Genet. 2008;16:1245-1253.
16. Azevedo MF, Faucz FR, Bimpaki E, et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev. 2014;35:195-233.
17. Libé R, Fratticci A, Coste J, et al. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res. 2008;14:4016-4024.
18. Vezzosi D, Libé R, Baudry C, et al. Phosphodiesterase 11A (PDE11A) gene defects in patients with ACTH-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contributetogenetic susceptibility of bilateral adrenal tumors. J Clin Endocrinol Metab. 2012;97:E2063-E2069.
19. Rothenbuhler A, Horvath A, Libé R, et al. Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. Clin Endocrinol (Oxf). 2012;77:195-199.
20. Libé R, Horvath A, Vezzosi D, et al. Frequent phosphodiesterase 11 Agene (PDE11A) defectsinpatients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J Clin Endocrinol Metab. 2011;96:E208-E214.
21. Beuschlein F, Fassnacht M, Assié G, et al. Constitutive activation of PKA catalytic subunit in a drenal Cushing's syndrome. N Engl J Med. 2014;370:1019-1028.
22. Cao Y, He M, Gao Z, et al. Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome. Science. 2014;344:913-917.
23. Sato Y, Maekawa S, Ishii R, et al. Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome. Science. 2014;344:917-920.
24. Goh G, Scholl UI, Healy JM, et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet. 2014;46:613-617.
25. Kirschner LS. Medicine. A unified cause for adrenal Cushing's syndrome. Science. 2014;344:804-805.
26. Sargent J. Neuroendocrine cancer. An activating hotspot mutation in PRKACA provides clues for adrenal Cushing syndrome therapeutics. Nat Rev Endocrinol. 2014;10:311.
27. Giordano TJ. Genetics: pinpointing a hotspot in adrenal Cushing syndrome. Nat Rev Endocrinol. 2014;10:447-448.
28. Di Dalmazi G, Kisker C, Calebiro D, et al. Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. J Clin Endocrinol Metab. 2014:99: E2093-E2100.
29. Bossis I, Stratakis CA. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology. 2004;145:5452-5458.
30. Meoli E, Bossis I, Cazabat L, et al. Protein kinase A effects of an expressed PRKAR1A mutation associated with aggressive tumors. Cancer Res. 2008;68:3133-3141.
31. Assié G. One single signaling pathway for so many different biological functions: lessons from the cyclic adenosine monophosphate/protein kinase A pathway-related diseases. J Clin Endocrinol Metab. 2012;97:4355-4357.
32. Linglart A, Menguy C, Couvineau A, et al. Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance. N Engl J Med. 2011;364:2218-2226.
33. Linglart A, Fryssira H, Hiort O, et al. PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct syndromes with or without GPCR-signaling hormone resistance. J Clin Endocrinol Metab. 2012;97:E2328-E2338.
34. Nagasaki K, Iida T, Sato H, et al. PRKAR1A mutation affecting cAMP-mediated G protein-coupled receptor signaling in a patient with acrodysostosis and hormone resistance. J Clin Endocrinol Metab. 2012;97:E1808-E1813.
35. Orellana SA, McKnight GS. Mutations in the catalytic subunit of cAMP-dependent protein kinase result in unregulated biological activity. Proc Natl Acad Sci USA. 1992;89:4726-4730.
36. Orellana SA, Amieux PS, Zhao X, McKnight GS. Mutations in the catalytic subunit of the cAMP-dependent protein kinase interfere with holoenzyme formation without disrupting inhibition by protein kinase inhibitor. J Biol Chem. 1993;268:6843-6846.
37. Kennedy EJ, Yang J, Pillus L, Taylor SS, Ghosh G. Identifying critical non-catalytic residues that modulate protein kinase A activity. PLoS One. 2009;4:e4746.
38. Søberg K, Larsen AC, Diskar M, et al. Identification and characterization of novel mutations in the human gene encoding the catalytic subunit Ca of protein kinase A (PKA). PLoS One. 2012;7:e34838.
39. Esapa CT, Harris PE. Mutation analysis of protein kinase A catalytic subunit in thyroid adenomas and pituitary tumours. Eur J Endocrinol. 1999;141:409-412.
40. Salpea P, Stratakis CA. Carney complex and McCune Albright syndrome: an overview of clinical manifestations and human molecular genetics. Mol Cell Endocrinol. 2014;386:85-91.
41. Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014;343:1010-1014.
42. Griffin KJ, Kirschner LS, Matyakhina L, et al. Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors. Cancer Res. 2004;64:8811-8815.
43. Veugelers M, Wilkes D, Burton K, et al. Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proc Natl Acad Sci USA. 2004;101:14222-14227.
44. Gennari M, Stratakis CA, Hovarth A, Pirazzoli P, Cicognani A. A novel PRKAR1A mutation associated with hepatocellular carcinoma in a young patient and a variable Carney complex phenotype in affected subjects in older generations. Clin Endocrinol (Oxf). 2008;69:751-755.
45. Moody SE, Schinzel AC, Singh S, et al. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores antiapoptotic signaling [published online June 9, 2014]. Oncogene. doi: 10/1038/onc.2014.153.
46. Kirschner LS, Kusewitt DF, Matyakhina L, et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res. 2005;65:4506-4514.
47. Tsang KM, Starost MF, Nesterova M, et al. Alternate protein kinase A activity identifies a unique population of stromal cells in adult bone. Proc Natl Acad Sci USA. 2010;107:8683-8688.
48. Skålhegg BS, Huang Y, Su T, Idzerda RL, McKnight GS, Burton KA. Mutation of the Ca subunit of PKA leads to growth retardation and sperm dysfunction. Mol Endocrinol. 2002;16:630-639.
49. Forlino A, Vetro A, Garavelli L, et al. PRKACB and Carney complex. N Engl J Med. 2014;370:1065-1067.
50. Yin Z, Pringle DR, Jones GN, Kelly KM, Kirschner LS. Differential role of PKA catalytic subunits in mediating phenotypes caused by knockout of the Carney complex gene Prkar1a. Mol Endocrinol. 2011;25:1786-1793.
51. Aimes RT, Hemmer W, Taylor SS. Serine-53 at the tip of the glycinerich loop of cAMP-dependent protein kinase: role in catalysis, P-site specificity, and interaction with inhibitors. Biochemistry. 2000;39:8325-8332.
52. Niswender CM, Ishihara RW, Judge LM, Zhang C, Shokat KM, McKnight GS. Protein engineering of protein kinase A catalytic subunits results in the acquisition of novel inhibitor sensitivity. J Biol Chem. 2002;277:28916-28922.